Promising Heart Failure Drug Fast-Tracked for Approval

Friday, 21 Jun 2013 08:01 AM

 

Share:
A    A   |
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Novartis AG won “breakthrough”status from U.S. regulators for an experimental drug to treat acute heart failure, raising the prospect of faster approval.
 
Serelaxin, a man-made version of a hormone found in pregnant women, reduced death rates by 37 percent in patients with acute heart failure six months after treatment, according to clinical trial results presented last year.
 
Also known as RLX030, The drug is Basel, Switzerland-based Novartis’s second to receive the new designation from the U.S. Food and Drug Administration after the lung-cancer treatment LDK378. Faster approvals of the two drugs would provide a sales boost for Novartis, Europe’s biggest drugmaker, just as the company’s best-selling products are losing patent protection.
 
“Commonly used medicines for AHF only improve the immediate symptoms, so the additional effect on survival observed with RLX030 offers hope to patients and physicians,” David Epstein, division head of Novartis Pharmaceuticals, said in a statement Friday.
 
Novartis’s Diovan hypertension drug started to lose patent protection last year. Gleevec, a cancer treatment, will be open to copies starting in 2015. Together, they generated $9.1 billion in sales last year. The company has filed for approval of Serelaxin in the U.S. and the European Union.
 
Other therapies that have received the breakthrough designation since it was established last year include Pfizer’s breast-cancer drug palbociclib and Johnson & Johnson and Pharmacyclics Inc.’s ibrutinib for certain types of blood cancer. Xalkori was approved in 2011, before the FDA program was introduced.
 
Acute heart failure often occurs in the wake of other ailments such as hypertension, diabetes or coronary artery disease and may strike about one in 10 people over the age of 65. Doctors now use a mix of drugs and devices to help patients feel better, yet half of those hospitalized don’t survive longer than five years. RLX030 is a manufactured copy of relaxin-2, a hormone whose levels rise during pregnancy.

© Copyright 2014 Bloomberg News. All rights reserved.

Share:
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Reports of E-Cig Injuries Jump: FDA

Thursday, 17 Apr 2014 08:41 AM

Complaints of injury linked to e-cigarettes, from burns and nicotine toxicity to respiratory and cardiovascular problems . . .

Researchers Find 'Juno,' Key to Fertility

Thursday, 17 Apr 2014 08:31 AM

You can forget about the birds and the bees. If you really want to learn how babies are made, you need to know about Jun . . .

Glimmer of Hope Amid US Diabetes Epidemic

Wednesday, 16 Apr 2014 17:43 PM

In the midst of the diabetes epidemic, a glimmer of good news: Heart attacks, strokes and other complications from the d . . .

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved